Stocks Health care SUPN
NASDAQ · Health careSupernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. brought in $865.1M of revenue over the twelve months to September 30, 2026, up 26.9% from a year earlier. It posted a net loss of $43.9M. Operating cash flow minus capital spending left $46M of free cash flow in fiscal 2025. At September 30, 2026 it held $175.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Supernus Pharmaceuticals, Inc.
- Net worth
- Supernus Pharmaceuticals, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $719M (+8.6% year on year), with a net loss of $38.6M. Over the 12 months to September 30, 2026: revenue $865.1M, net loss $43.9M.
- Cash flow
- In fiscal 2025 operations brought in $47.3M of cash; after $1.3M of capital spending, free cash flow was $46M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Supernus Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Supernus Pharmaceuticals, Inc. does
Supernus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SUPN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $719M | -$38.6M | -$0.68 | $46M |
| 2024 | $661.8M | $73.9M | $1.32 | $171.2M |
| 2024 | $607.5M | $1.3M | $0.02 | $110.5M |
| 2022 | $667.2M | $60.7M | $1.04 | $116.4M |
| 2021 | $579.8M | $53.4M | $0.98 | n/a |
| 2020 | $520.4M | $127M | $2.36 | $135M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SUPN ranks in Health care
Latest SEC filings
What Supernus Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026Delisting notice 25-NSE
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026Form S-8 POS filing S-8 POS
- November 2, 2026
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 18% to $226.8M versus the same quarter last year; diluted EPS $0.35 versus -$0.80.
What is SUPN worth? A DCF from its reported cash flow
Insider trades
What the people running Supernus Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 10 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Newhall Charles W IIIDirector | Other change | 124,119 | - |
| November 2, 2026 | Dec Timothy CSenior Vice-President & CFO | Other change | 9,129 | - |
| November 2, 2026 | Gemayel GeorgesDirector | Other change | 27,277 | - |
| November 2, 2026 | Hudson Frederick M.Director | Other change | 60,413 | - |
| November 2, 2026 | Bhatt Padmanabh P.Sr. VP of IP, CSO | Other change | 18,637 | - |
| November 2, 2026 | Khattar Jack A.President, CEO, Director | Other change | 1,258,351 | - |
| November 2, 2026 | Khattar Jack A.President, CEO, Director | Other changeindirect | 958,100 | - |
| November 2, 2026 | Barlow CarroleeDirector | Other change | 27,045 | - |
Who owns SUPN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Millennium Management LLC13G, passive with 3 related filers | 6.6% | August 6, 2026 |
| Vanguard Portfolio Management13G, passive | 5.66% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.03% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 333 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 9,350,046 | +552,792 |
| Millennium Management LLC | 3,853,212 | +537,239 |
| Vanguard Portfolio Management LLC | 3,305,429 | +66,736 |
| Armistice Capital, LLC | 2,646,201 | +750,854 |
| Vanguard Capital Management LLC | 2,516,721 | +49,506 |
| State Street Corp | 2,459,828 | +171,701 |
| Nomura Asset Management International Inc. | 2,378,329 | +341,127 |
| Dimensional Fund Advisors LP | 2,078,090 | -228,940 |
| Geode Capital Management, LLC | 1,570,088 | -53,426 |
| Stephens Investment Management Group LLC | 1,485,821 | +134,490 |
| Renaissance Technologies LLC | 1,478,180 | -227,042 |
| Loomis Sayles & Co L P | 1,475,192 | +49,413 |
| Citadel Advisors LLC | 1,373,982 | -119,464 |
| Two Sigma Investments, LP | 1,184,378 | +913,150 |
| Sofinnova Investments, Inc. | 1,036,328 | +82,019 |
| Qube Research & Technologies Ltd | 922,166 | +423,968 |
| Morgan Stanley | 876,841 | -37,052 |
| Goldman Sachs Group Inc | 819,432 | -37,055 |
| D. E. Shaw & Co., Inc. | 767,668 | +145,218 |
| Northern Trust Corp | 733,374 | +33,918 |
Insiders
Questions about SUPN
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as SUPN. Its shares trade on NASDAQ under the ticker SUPN.
What is Supernus Pharmaceuticals, Inc.'s net worth?
Supernus Pharmaceuticals, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Supernus Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $43.9M on revenue of $865.1M.
How much revenue does Supernus Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Supernus Pharmaceuticals, Inc. reported revenue of $865.1M. That is 26.9% more than a year earlier.
When did Supernus Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Supernus Pharmaceuticals, Inc.'s next earnings report?
Supernus Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SUPN with
Follow SUPN
Get an email when Supernus Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Supernus Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.